{
    "clinical_study": {
        "@rank": "53470", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: MK-7009 alone", 
                "arm_group_type": "Experimental", 
                "description": "Participants in this study group will receive MK-7009 alone and will have liver biopsy done by FNA and CNB."
            }, 
            {
                "arm_group_label": "Treatment B: MK-7009 High Dose + Peg-IFN alpha-2b + RBV", 
                "arm_group_type": "Experimental", 
                "description": "Participants in this study group will receive MK-7009, Peg-IFN alpha-2b, and RBV and will have liver biopsy done by FNA and CNB."
            }, 
            {
                "arm_group_label": "Treatment C: MK-7009 MK-7009 Low Dose + Peg-IFN alpha-2b + RBV", 
                "arm_group_type": "Experimental", 
                "description": "Participants in this study group will receive MK-7009, Peg-IFN alpha-2b, and RBV and will have liver biopsy done by FNA and CNB."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the technical feasibility of using fine needle aspiration (FNA) of\n      liver tissue to obtain MK-7009 liver pharmacokinetic (PK) data, working towards identifying\n      a minimally invasive, reproducible platform to measure liver PK. The study will be done in 2\n      parts. In Part 1, participants will be randomized to one of five FNA/core needle biopsy\n      (CNB) time-point collection sequences. In Part 2, participants will be randomized to one of\n      two possible doses of MK-7009 and will be assigned to one of five FNA/CNB time-point\n      collection sequences; participants in Part 2 will also receive background therapy with\n      pegylated interferon alpha-2b (Peg-IFN alpha-2b) and ribavirin (RBV)."
        }, 
        "brief_title": "A Study to Evaluate Fine Needle Aspiration as a Method for MK-7009 Liver Pharmacokinetic Measurement in Participants With Chronic Hepatitis C (MK-7009-048)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index (BMI) \u226518.5 kg/m^2 and \u226432.0 kg/m^2\n\n          -  Under evaluation for treatment of chronic hepatitis C virus (HCV)\n\n          -  Chronic compensated, genotype 1 HCV infection\n\n          -  Treatment-na\u00efve or previously treated and tolerated at least 12 weeks of continuous\n             licensed interferon (including pegylated interferon) and ribavirin combination\n             therapy with at least a partial response, or previously treated with investigational\n             products and/or vaccines, other than NS3/4A protease inhibitors, either alone or in\n             combination with other licensed therapies\n\n          -  Able to avoid use of anticoagulants, nonsteroidal anti-inflammatory agents and\n             aspirin for at least seven (7) days preceding the initial liver biopsy and continuing\n             throughout the entire study\n\n          -  Female participants of childbearing potential or male participants with female sexual\n             partners of childbearing potential must agree to use two acceptable methods of birth\n             control from 2 weeks prior to the first dose through at least 6 months after last\n             dose of study drug, or longer if dictated by local regulation\n\n        Exclusion criteria:\n\n          -  Pregnant, lactating, or intending to become pregnant or donate eggs, or intending to\n             donate sperm\n\n          -  History of stroke, chronic seizures, or major neurological disorder\n\n          -  Did not achieve a viral response to prior treatment with licensed interferon-based\n             therapy\n\n          -  Previously treated with an NS3/4A protease inhibitor (investigational or licensed)\n\n          -  Evidence or history of chronic hepatitis not caused by HCV infection including but\n             not limited to non-HCV viral hepatitis, nonalcoholic steatohepatitis (NASH),\n             drug-induced hepatitis or autoimmune hepatitis\n\n          -  Clinical or laboratory evidence of cirrhosis or other advanced liver disease\n\n          -  Decompensated liver disease as indicated by a history of ascites, hepatic\n             encephalopathy, or bleeding esophageal varices\n\n          -  Diagnosed with or suspected of having hepatocellular carcinoma\n\n          -  Co-infection with human immunodeficiency virus (HIV)\n\n          -  Positive hepatitis B surface antigen or other evidence of active hepatitis B\n             infection\n\n          -  History of gastric bypass surgery or bowel resection\n\n          -  History of clinically significant uncontrolled endocrine, gastrointestinal,\n             cardiovascular, hematological, immunological, renal, respiratory, or genitourinary\n             abnormalities or diseases\n\n          -  History of clinically significant neoplastic disease\n\n          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of\n             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL], wine [125\n             mL], or distilled spirits [25 mL]) per day\n\n          -  Regular user (including use of any illicit drugs or has a history of drug (including\n             alcohol) abuse within the last 3 months\n\n          -  Surgery or donation of 1 unit of blood (approximately 500 mL) or participation in\n             another investigational study within a period of 4 weeks prior to the prestudy\n             (screening) visit\n\n          -  History of multiple and/or severe allergies, or has had an anaphylactic reaction or\n             intolerability to prescription or nonprescription drugs or food"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678131", 
            "org_study_id": "7009-048", 
            "secondary_id": "2012-003284-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A: MK-7009 alone", 
                    "Treatment B: MK-7009 High Dose + Peg-IFN alpha-2b + RBV", 
                    "Treatment C: MK-7009 MK-7009 Low Dose + Peg-IFN alpha-2b + RBV"
                ], 
                "description": "MK-7009 capsules, orally, twice per day (BID) on Days 1 through 6 and a single dose, orally, on Day 7.", 
                "intervention_name": "MK-7009", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment B: MK-7009 High Dose + Peg-IFN alpha-2b + RBV", 
                    "Treatment C: MK-7009 MK-7009 Low Dose + Peg-IFN alpha-2b + RBV"
                ], 
                "description": "Administered per product label", 
                "intervention_name": "Peg-IFN alfa-2b", 
                "intervention_type": "Biological", 
                "other_name": "PegIntron\u2122"
            }, 
            {
                "arm_group_label": [
                    "Treatment B: MK-7009 High Dose + Peg-IFN alpha-2b + RBV", 
                    "Treatment C: MK-7009 MK-7009 Low Dose + Peg-IFN alpha-2b + RBV"
                ], 
                "description": "Administered per product label", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Biological", 
                "other_name": "Rebetol\u2122"
            }, 
            {
                "arm_group_label": [
                    "Treatment A: MK-7009 alone", 
                    "Treatment B: MK-7009 High Dose + Peg-IFN alpha-2b + RBV", 
                    "Treatment C: MK-7009 MK-7009 Low Dose + Peg-IFN alpha-2b + RBV"
                ], 
                "intervention_name": "Liver samples from FNA and CNB", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon Alfa-2a", 
                "Interferon-alpha", 
                "Interferon Alfa-2b", 
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 24, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-7009 in Chronic Hepatitis C Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of participants from whom detectable concentrations of hepatic MK-7009 are obtained by fine needle aspiration (FNA)", 
            "safety_issue": "No", 
            "time_frame": "Days 7 through 10, at a randomized sequence of 3 out of 5 possible collection time points (3, 12, 24, 48, or 72 hours post dose)"
        }, 
        "removed_countries": {
            "country": "Moldova, Republic of"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678131"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}